An interventional study of SAPIEN 3/SAPIEN 3 Ultra RESILIA THV and SAPIEN 3 THV in Complex Congenital Heart Defect, Dysfunctional RVOT Conduit and Pulmonary Valve Insufficiency, sponsored by Edwards Lifesciences. Recruiting at 27 sites in United States. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Valve Insufficiency with a site in United States — 2 open to participants now, 8 under way, none of them phase 3. Pulmonary Valve Insufficiency · United States.
Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 10 with no phase, and was the 7th registered.
31 studies on the registry are indexed under Pulmonary Valve Insufficiency; 8 are open to participants now.
Browse Pulmonary Valve Insufficiency studies →2 of the 15 studies in Pulmonary Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Venus MedTech (HangZhou) Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Pulmonary Valve Insufficiency studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2016.
This study's planned enrollment of 108 is above the median of 60 across 21 interventional studies indexed under Pulmonary Valve Insufficiency.
Median enrollment 75 across the 10 interventional studies, 140 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 15 have an industry lead sponsor. The 9 most frequent:
Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.
Edwards Lifesciences has 8 studies filed under Pulmonary Valve Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Pulmonary Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT02744677Edwards LifesciencesCOMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
Device: SAPIEN 3 THV
Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
Device: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV
Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
Device: SAPIEN 3 Ultra RESILIA THV
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position
SAPIEN 3 THV in the pulmonic position
SAPIEN 3 Ultra RESILIA THV in the pulmonic position
THV dysfunction
Defined as a non-hierarchical composite of: RVOT reintervention, Moderate or greater total pulmonary regurgitation (PR) via Transthoracic Echocardiography (TTE), Mean RVOT gradient \> 40 mmHg via TTE
Time frame: 1 year
Device Success
Defined as a composite of: 1) Single THV implanted in the desired location, 2) RV-PA peak-to-peak gradient \< 35 mmHg post-implantation, 3) Less than moderate PR by discharge TTE (or earliest evaluable TTE), 4) Free of explant at 24 hours post-implantation.
Time frame: Discharge, expected to be within 1-5 days post-procedure
Mean RVOT gradient
Time frame: 6 months
Paravalvular and total PR
Time frame: 6 months
RVOT reintervention
Time frame: 6 months
Coronary artery compression requiring intervention
Time frame: 30 days
Major vascular complications
Time frame: 30 days
Life-threatening or disabling bleeding
Time frame: 30 days
THV frame fracture
Time frame: 6 months
Device-related endocarditis
Time frame: 1 year
Death (all-cause, procedural and device-related)
Time frame: 1 year
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Jul 2016 (actual). Primary completion is estimated for Dec 2026, 125 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Valve Insufficiency →